Roivant Sciences (ROIV) Assets (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Assets came in at $5.7 billion in Q1 2026, up 5.0% YoY from $5.4 billion in Q1 2025, and up 9.25% on a QoQ basis from $5.2 billion in Q4 2025.
Roivant Sciences (ROIV) Assets (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Assets data on file, last reported at $5.7 billion in Q1 2026.
- Quarterly Assets rose 5.0% year-over-year to $5.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 billion (up 5.0% YoY) and the FY2026 annual result came in at $5.7 billion, up 5.0% from the prior year.
- Assets grew to $5.7 billion in Q1 2026, from $5.2 billion in the prior quarter.
- In the past five years, Assets ranged from a high of $7.3 billion in Q4 2023 to a low of $2.1 billion in Q3 2023.
- A 5-year average of $4.5 billion and a median of $5.1 billion in 2025 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets slipped 28.6% — and 2023, when it soared 231.95%.
- Tracing ROIV's Assets over 5 years: stood at $2.2 billion in 2022, then soared by 231.95% to $7.3 billion in 2023, then fell by 20.79% to $5.8 billion in 2024, then fell by 9.79% to $5.2 billion in 2025, then rose by 9.25% to $5.7 billion in 2026.
- The last three Assets figures came in at $5.7 billion (Q1 2026), $5.2 billion (Q4 2025), and $5.1 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.31 Bn |
| Mar 31, 2026 | 5.71 Bn |
| Dec 31, 2025 | 5.23 Bn |
| Sep 30, 2025 | 5.06 Bn |
| Jun 30, 2025 | 5.03 Bn |
| Mar 31, 2025 | 5.44 Bn |
| Dec 31, 2024 | 5.79 Bn |
| Sep 30, 2024 | 6.21 Bn |
| Jun 30, 2024 | 6.50 Bn |
| Mar 31, 2024 | 7.22 Bn |
| Dec 31, 2023 | 7.31 Bn |
| Sep 30, 2023 | 2.07 Bn |
| Jun 30, 2023 | 2.14 Bn |
| Mar 31, 2023 | 2.39 Bn |
| Dec 31, 2022 | 2.20 Bn |
| Sep 30, 2022 | 2.22 Bn |
| Jun 30, 2022 | 2.60 Bn |
| Mar 31, 2022 | 2.59 Bn |
| Dec 31, 2021 | 2.80 Bn |
| Sep 30, 2021 | 3.10 Bn |